{"id":821709,"date":"2025-03-04T16:35:06","date_gmt":"2025-03-04T21:35:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/"},"modified":"2025-03-04T16:35:06","modified_gmt":"2025-03-04T21:35:06","slug":"supernus-to-participate-in-two-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/","title":{"rendered":"Supernus to Participate in Two Upcoming Investor Conferences"},"content":{"rendered":"
\n

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:<\/p>\n\n\n\n\n\n\n\n\n\n\n
\n Barclays Global Healthcare Conference<\/u>\n <\/td>\n<\/tr>\n
Date:<\/td>\n\u00a0<\/td>\nTuesday, March 11, 2025<\/td>\n<\/tr>\n
Fireside chat:\u00a0<\/td>\n\u00a0<\/td>\n12:30 p.m. ET<\/td>\n<\/tr>\n
Place:<\/td>\n\u00a0<\/td>\nLoews Miami Beach Hotel, Miami, Fla.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Jefferies Biotech on the Beach Summit<\/u>\n <\/td>\n<\/tr>\n
Date:<\/td>\n\u00a0<\/td>\nWednesday, March 12, 2025<\/td>\n<\/tr>\n
Place:<\/td>\n\u00a0<\/td>\nRitz-Carlton South Beach, Miami, Fla.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the respective conference coordinators.<\/p>\n

A live audio webcast of the Company\u2019s fireside chat at the Barclays Global Healthcare Conference can be accessed here<\/a> or by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com<\/a>. An archived replay of the webcast will be available for 60 days on the Company’s website following the conference.<\/p>\n

\n About Supernus Pharmaceuticals, Inc. <\/strong>\n <\/p>\n

Supernus Pharmaceuticals\u00a0is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.<\/p>\n

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson\u2019s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.<\/p>\n

For more information, please visit\u00a0www.supernus.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company\u2019s ability to sustain and increase its profitability; the Company\u2019s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company\u2019s corporate strategy; the Company\u2019s future financial performance and projected expenditures; the Company\u2019s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company\u2019s ability to increase its net revenue; the Company\u2019s ability to commercialize its products and the products of its subsidiaries; the Company\u2019s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company\u2019s product research and development activities, including the timing and progress of the Company\u2019s clinical trials, and projected expenditures; the Company\u2019s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company\u2019s product candidates; the Company\u2019s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company\u2019s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company\u2019s product candidates; the accuracy of the Company\u2019s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company\u2019s ability to increase its manufacturing capabilities for its products and product candidates; the Company\u2019s projected markets and growth in markets; the Company\u2019s product formulations and patient needs and potential funding sources; the Company\u2019s staffing needs; and other risk factors set forth from time to time in the Company\u2019s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.<\/p>\n

\n CONTACTS:<\/strong>\n <\/p>\n

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or<\/p>\n

\n INVESTOR CONTACT:<\/strong>\n <\/p>\n

Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Barclays Global Healthcare Conference Date: \u00a0 Tuesday, March 11, 2025 Fireside chat:\u00a0 \u00a0 12:30 p.m. ET Place: \u00a0 Loews Miami Beach Hotel, Miami, Fla. \u00a0 \u00a0 \u00a0 Jefferies Biotech on the Beach Summit Date: \u00a0 Wednesday, March 12, 2025 Place: \u00a0 Ritz-Carlton South Beach, Miami, Fla. \u00a0 \u00a0 \u00a0 Investors interested in arranging a meeting with the Company’s management during these conferences should contact the respective conference coordinators. A live … <\/p>\n

Continue reading “Supernus to Participate in Two Upcoming Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-821709","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSupernus to Participate in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Supernus to Participate in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Barclays Global Healthcare Conference Date: \u00a0 Tuesday, March 11, 2025 Fireside chat:\u00a0 \u00a0 12:30 p.m. ET Place: \u00a0 Loews Miami Beach Hotel, Miami, Fla. \u00a0 \u00a0 \u00a0 Jefferies Biotech on the Beach Summit Date: \u00a0 Wednesday, March 12, 2025 Place: \u00a0 Ritz-Carlton South Beach, Miami, Fla. \u00a0 \u00a0 \u00a0 Investors interested in arranging a meeting with the Company’s management during these conferences should contact the respective conference coordinators. A live … Continue reading "Supernus to Participate in Two Upcoming Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T21:35:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Supernus to Participate in Two Upcoming Investor Conferences\",\"datePublished\":\"2025-03-04T21:35:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/\"},\"wordCount\":703,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/\",\"name\":\"Supernus to Participate in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=\",\"datePublished\":\"2025-03-04T21:35:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/supernus-to-participate-in-two-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Supernus to Participate in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Supernus to Participate in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Supernus to Participate in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Barclays Global Healthcare Conference Date: \u00a0 Tuesday, March 11, 2025 Fireside chat:\u00a0 \u00a0 12:30 p.m. ET Place: \u00a0 Loews Miami Beach Hotel, Miami, Fla. \u00a0 \u00a0 \u00a0 Jefferies Biotech on the Beach Summit Date: \u00a0 Wednesday, March 12, 2025 Place: \u00a0 Ritz-Carlton South Beach, Miami, Fla. \u00a0 \u00a0 \u00a0 Investors interested in arranging a meeting with the Company’s management during these conferences should contact the respective conference coordinators. A live … Continue reading \"Supernus to Participate in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-04T21:35:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Supernus to Participate in Two Upcoming Investor Conferences","datePublished":"2025-03-04T21:35:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/"},"wordCount":703,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/","name":"Supernus to Participate in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=","datePublished":"2025-03-04T21:35:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODEyMyM2Nzg3ODY0IzIwMTA5NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/supernus-to-participate-in-two-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Supernus to Participate in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=821709"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821709\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=821709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=821709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=821709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}